Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Public ClinicalTrials.gov record NCT00118209. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This randomized phase III trial studies rituximab when given together with two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell non-Hodgkin's lymphoma. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving rituximab together with combination chemotherapy may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective when given with rituximab in treating diffuse large B-cell non-Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying rituximab when given together with two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell lymphoma.
Study identification
- NCT ID
- NCT00118209
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 524 participants
Conditions and interventions
Conditions
Interventions
- rituximab Biological
- cyclophosphamide Drug
- doxorubicin Drug
- vincristine Drug
- prednisone Drug
- etoposide Drug
- filgrastim Drug
- pegfilgrastim Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2005
- Primary completion
- Sep 30, 2017
- Completion
- Nov 14, 2021
- Last update posted
- Nov 16, 2021
2005 – 2021
United States locations
- U.S. sites
- 47
- U.S. states
- 18
- U.S. cities
- 41
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Rebecca and John Moores UCSD Cancer Center | La Jolla | California | 92093-0658 | — |
| Camino Medical Group - Treatment Center | Mountain View | California | 94040 | — |
| Palo Alto Medical Foundation | Palo Alto | California | 94301 | — |
| Naval Medical Center - San Diego | San Diego | California | 92134 | — |
| Saint Helena Hospital | St. Helena | California | 94574 | — |
| Eastern Connecticut Hematology and Oncology Associates | Norwich | Connecticut | 06360 | — |
| CCOP - Christiana Care Health Services | Newark | Delaware | 19713 | — |
| Robert H. Lurie Comprehensive Cancer Center at Northwestern University | Chicago | Illinois | 60611-3013 | — |
| University of Illinois Cancer Center | Chicago | Illinois | 60612-7243 | — |
| Creticos Cancer Center at Advocate Illinois Masonic Medical Center | Chicago | Illinois | 60657 | — |
| Cardinal Bernardin Cancer Center at Loyola University Medical Center | Maywood | Illinois | 60153 | — |
| Alvin and Lois Lapidus Cancer Institute at Sinai Hospital | Baltimore | Maryland | 21215 | — |
| National Naval Medical Center | Bethesda | Maryland | 20889-5600 | — |
| NIH - Warren Grant Magnuson Clinical Center | Bethesda | Maryland | 20892-1182 | — |
| Providence Cancer Institute at Providence Hospital - Southfield Campus | Southfield | Michigan | 48075 | — |
| Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis | St Louis | Missouri | 63110 | — |
| Christian Hospital Northeast-Northwest | St Louis | Missouri | 63136 | — |
| New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care | Concord | New Hampshire | 03301 | — |
| New Hampshire Oncology - Hematology, PA - Hooksett | Hooksett | New Hampshire | 03106 | — |
| Charles R. Wood Cancer Center at Glens Falls Hospital | Glens Falls | New York | 12801 | — |
| New York Weill Cornell Cancer Center at Cornell University | New York | New York | 10021 | — |
| James P. Wilmot Cancer Center at University of Rochester Medical Center | Rochester | New York | 14642 | — |
| Presbyterian Cancer Center at Presbyterian Hospital | Charlotte | North Carolina | 28233-3549 | — |
| Kinston Medical Specialists | Kinston | North Carolina | 28501 | — |
| Iredell Memorial Hospital | Statesville | North Carolina | 28677 | — |
| Wake Forest University Comprehensive Cancer Center | Winston-Salem | North Carolina | 27157-1096 | — |
| Altru Cancer Center at Altru Hospital | Grand Forks | North Dakota | 58201 | — |
| Mercy Cancer Center at Mercy Medical Center | Canton | Ohio | 44708 | — |
| Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210-1240 | — |
| Geisinger Cancer Institute at Geisinger Health | Danville | Pennsylvania | 17822-0001 | — |
| Easton Regional Cancer Center at Easton Hospital | Easton | Pennsylvania | 18042 | — |
| Geisinger Hazleton Cancer Center | Hazleton | Pennsylvania | 18201 | — |
| Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center | Hershey | Pennsylvania | 17033-0850 | — |
| Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital | Pittsburgh | Pennsylvania | 15224-1791 | — |
| Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center | Wilkes-Barre | Pennsylvania | 18711 | — |
| Mountainview Medical | Berlin Corners | Vermont | 05602 | — |
| Virginia Commonwealth University Massey Cancer Center | Richmond | Virginia | 23298-0037 | — |
| Madigan Army Medical Center - Tacoma | Tacoma | Washington | 98431 | — |
| Mary Babb Randolph Cancer Center at West Virginia University Hospitals | Morgantown | West Virginia | 26506 | — |
| Marshfield Clinic - Marshfield Center | Marshfield | Wisconsin | 54449 | — |
| Saint Joseph's Hospital | Marshfield | Wisconsin | 54449 | — |
| Marshfield Clinic - Lakeland Center | Minocqua | Wisconsin | 54548 | — |
| Ministry Medical Group at Saint Mary's Hospital | Rhinelander | Wisconsin | 54501 | — |
| Marshfield Clinic - Indianhead Center | Rice Lake | Wisconsin | 54868 | — |
| Marshfield Clinic at Saint Michael's Hospital | Stevens Point | Wisconsin | 54481 | — |
| Saint Michael's Hospital Cancer Center | Stevens Point | Wisconsin | 54481 | — |
| Marshfield Clinic - Weston Center | Weston | Wisconsin | 54476 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Large B Cell Lymphoma trials
Other public records listing Large B Cell Lymphoma. Sorted by last update posted; newest first. Not a recommendation.
- NCT07608731: Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas Not yet recruiting
- NCT07711483: GLORY: Glofit-GemOx With Liso-Cel For Lymphoma Not yet recruiting
- NCT05464719: A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy Recruiting
- NCT06047080: An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma Active, not recruiting
- NCT07188558: A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy Recruiting
- NCT06500273: Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00118209, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 16, 2021 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00118209 live on ClinicalTrials.gov.